Brief: Pediatrix Medical Group Q2 Revenue USD 468.844 Million Vs. IBES Estimate USD 464.3 Million

Pediatrix Medical

05/08/2025 11:00

Overview

Pediatrix Q2 revenue beats analyst expectations, driven by neonatology volumes

Adjusted EBITDA for Q2 exceeds estimates

Company raises full-year 2025 adjusted EBITDA outlook

Outlook

Pediatrix raises full-year 2025 Adjusted EBITDA outlook to $245 mln-$255 mln

Company remains cautious amid turbulent healthcare environment

Company believes financial flexibility provides safety and opportunity

Result Drivers

NEONATOLOGY VOLUMES - Strong neonatology patient volumes contributed to increased same-unit revenue

PAYOR MIX - Stable payor mix and improved collection activity supported revenue

PRACTICE DISPOSITIONS - Decrease in net revenue due to practice dispositions, offset by same-unit growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$468.84 mln
$464.30 mln (8 Analysts)
Q2 Net Income
$39.26 mln
Q2 Adjusted EBITDA
Beat
$73.25 mln
$59.70 mln (7 Analysts)
Q2 Income from operations
$59.87 mln
Q2 Operating Expenses
$408.98 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Pediatrix Medical Group Inc is $16.00, about 23.1% above its August 4 closing price of $12.30

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nBw3s3pRBa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)